New research reveals light sensitivity significantly impacts quality of life in myasthenia gravis patients, highlighting the ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...

The American Journal of Managed Care provides insights into the latest news and research in managed care across multimedia ...

Winnacunnet High School senior Joe Labrecque has transformed his battle with a rare chronic illness into a mission to help ...

FREDERICK, Md., May 08, 2025 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the "Company”), a clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, ...

During tests in a Chinese factory, a humanoid robot suffered a malfunction and lashed out wildly, as a video shows. The test engineers switched off the robot in time before it could injure anyone.

The FDA has approved Johnson & Johnson’s drug Imaavy for the treatment of generalized myasthenia gravis, a chronic autoimmune neuromuscular disorder. The approval covers adults and pediatric patients ...

The US Food and Drug Administration (FDA) has approved nipocalimab (Imaavy) injection for the treatment of adults and children aged 12 and older with generalized myasthenia gravis (gMG) who are ...

Drug tests will be carried out more regularly in a prison where almost 40% of tests have been found to come back positive. The Ministry of Justice (MoJ) has outlined how it planned to solve ...

Biotechnology startups usually turn to a few tried-and-true options to raise the money they need to develop a new drug. Company founders might get initial financial help from friends, family or an ...

Imaavy is the first FcRn blocker approved for anti-AChR and anti-MuSK antibody positive patients with generalized myasthenia gravis. The Food and Drug Administration (FDA) has approved Imaavy ...